GlassScriptPhysician profile
Merije T Chukumerije
NPI 1235557356
$20,615.40
in general payments reported to CMS, 2019-2025
14 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $495 · 2021: $2,125 · 2022: $157 · 2024: $2,730 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,320 · Travel and Lodging: $1,074 · Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,320.00 |
| Travel and Lodging | $1,073.86 |
| Food and Beverage | $545.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14,982.87 | 2024-2025 | Shingrix |
| Eko Health, INC. | $2,273.99 | 2020-2021 | |
| Lilly USA, LLC | $1,320.00 | 2024 | Jardiance |
| Medtronic Vascular, INC. | $1,159.85 | 2019 | |
| Abbott Laboratories | $203.53 | 2019-2020 | |
| Medtronic, INC. | $165.80 | 2025 | Affera Mapping System |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2021 | |
| Boston Scientific Corporation | $121.61 | 2019 | |
| Biosense Webster, INC. | $108.58 | 2022 | |
| Celgene Corporation | $48.43 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.28 | 2020 | |
| Novartis Pharmaceuticals Corporation | $27.55 | 2025 | |
| Edwards Lifesciences Corporation | $26.74 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.17 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merije Chukumerije listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.